More and more people across Europe are finding it hard to access high-quality cancer care in the wake of years of public spending cuts. This Editorial looks at some initiatives to address growing inequalities and argues that everyone involved in planning and providing treatment and care has a key role and responsibility .
Understanding how cancer wreaks its havoc on the human body is important for the head of the International Agency for Research on Cancer, but his main concern is how to stop it.
Advances in imaging and molecular biology are opening up a wealth of new avenues for research and treatment in radiotherapy. But could progress be held back by a lack of public awareness of the potential for innovation?
Epidemiologists have long been warning of the rapid rise in cancer rates hitting low- and middle-income countries. But it takes a journalist to get across how those statistics are playing out in peopleÂ’s lives. Jason Gale, who covers Asian Healthcare for Bloomberg Markets, received a Best Cancer Reporter Award for his piece on the cost of cancer in India, reprinted below.
Karol Sikora, a medical oncologist who has directed cancer services at a major London hospital, triggered an angry reaction earlier this year when he suggested that younger patients should have priority when it comes to accessing very expensive, potentially life extending, cancer therapies. But did he have a point? we asked Ulrich Wedding, a specialist in cancer in the elderly and a board member of the International Society of Geriatric Oncology, to debate the issue with Sikora to see if they could find any common ground
Â“I have learned to shift from seeing myself as invulnerable to quite vulnerable Â– and to know that as not something to push away. There are good things about vulnerability. I have never felt so loved, supported, treasuredÂ… and have come to know some people in a way I think I never would otherwise.Â”
Skin rash and itchy skin are known to be common side-effects in patients treated with EGFR and tyrosine kinase inhibitors, and can be distressing, particularly when severe. A growing understanding of why this happens is leading to new ways of managing the problem
Doctors in Tel Aviv teamed up with a photojournalist to learn more about the role of the Â‘unsung heroesÂ’ who place their patientÂ–companion at the heart of their world.
Cytotoxic agents are conventionally dosed on the basis of the maximum tolerated dose defined in phase I trials. A study assessing adverse events in over 2,000 patients treated with molecularly targeted agents suggests a need to redefine criteria for dosing of molecularly targeted agents, which should be based on randomised, dose-ranging phase II trials.
Selected reports edited by Janet Fricker